Computational identification and experimental validation of microRNAs binding to the fragile X syndrome gene Fmr1

Xi Gong1, Yanlu Wang, Jianping Zeng

  • 1State Key Laboratory of Food Science and Technology, College of Life Sciences, Nanchang University, Nanchang, 330031, China.

Neurochemical Research
|November 8, 2014
PubMed

Insights

MicroRNAs regulate gene expression. This study identified miR-124 as a key regulator of Fmr1, promoting embryonic stem cell proliferation by increasing Cdk4 and cyclin D1 levels.

Area of Science:

  • Molecular Biology
  • Genetics
  • Developmental Biology

Background:

  • MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally.
  • Fragile X mental retardation gene (Fmr1) plays a crucial role in neuronal development and function.
  • Dysregulation of Fmr1 is implicated in various neurological disorders.

Purpose of the Study:

  • To computationally predict and experimentally validate microRNAs targeting the Fmr1 gene.
  • To investigate the functional role of a specific microRNA, miR-124, in regulating Fmr1 expression and its impact on neural progenitor cell proliferation.

Main Methods:

  • Computational prediction of miRNA binding sites using TargetScan, miRDB, and miRanda.
  • Experimental validation of predicted miRNA-target interactions using luciferase reporter assays.
  • Overexpression of miR-124 in mouse embryonic neural progenitor cells (eNPCs) followed by analysis of Fmr1, Cdk4, and cyclin D1 levels and cell proliferation.

Main Results:

  • Identified 61 candidate miRNAs targeting Fmr1 predicted by all three computational tools.
  • Experimentally verified 5 miRNAs (miR-23a, miR-32, miR-124, miR-335-5p, miR-350) targeting Fmr1.
  • Overexpression of miR-124 significantly reduced Fmr1 levels and increased Cdk4 and cyclin D1 expression in eNPCs, promoting proliferation.

Conclusions:

  • miR-124 directly targets and inhibits Fmr1 expression.
  • miR-124 promotes mouse embryonic stem cell proliferation by upregulating Cdk4 and cyclin D1.
  • These findings highlight miR-124 as a potential therapeutic target for conditions involving Fmr1 dysregulation and impaired cell proliferation.